Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 1
2008 1
2009 2
2010 1
2011 1
2013 1
2014 4
2015 2
2016 3
2017 2
2018 3
2019 2
2020 3
2021 4
2022 5
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Vergote I, et al. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. J Clin Oncol. 2023. PMID: 37669480 Clinical Trial.
Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS).
Pérez-Fidalgo JA, Ortega E, Ponce J, Redondo A, Sevilla I, Valverde C, Isern Verdum J, de Alava E, Galera López M, Marquina G, Sebio A. Pérez-Fidalgo JA, et al. Ther Adv Med Oncol. 2023 Mar 28;15:17588359231157645. doi: 10.1177/17588359231157645. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37007636 Free PMC article. Review.
NOTCH signalling in ovarian cancer angiogenesis.
Perez-Fidalgo JA, Ortega B, Simon S, Samartzis EP, Boussios S. Perez-Fidalgo JA, et al. Ann Transl Med. 2020 Dec;8(24):1705. doi: 10.21037/atm-20-4497. Ann Transl Med. 2020. PMID: 33490217 Free PMC article. Review.
Melanoma of unknown primary: New perspectives for an old story.
Boussios S, Rassy E, Samartzis E, Moschetta M, Sheriff M, Pérez-Fidalgo JA, Pavlidis N. Boussios S, et al. Crit Rev Oncol Hematol. 2021 Feb;158:103208. doi: 10.1016/j.critrevonc.2020.103208. Epub 2020 Dec 28. Crit Rev Oncol Hematol. 2021. PMID: 33383207 Review.
Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601.
Perez-Fidalgo JA, Guerra E, García Y, Iglesias M, Hernández-Sosa M, Estevez-García P, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio MJ, González-Martín A. Perez-Fidalgo JA, et al. Int J Gynecol Cancer. 2023 Jun 5;33(6):929-936. doi: 10.1136/ijgc-2022-004028. Int J Gynecol Cancer. 2023. PMID: 36759001 Clinical Trial.
An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.
Chandarlapaty S, Dickler MN, Perez Fidalgo JA, Villanueva-Vázquez R, Giltnane J, Gates M, Chang CW, Cheeti S, Fredrickson J, Wang X, Collier A, Moore HM, Metcalfe C, Lauchle J, Humke EW, Bardia A. Chandarlapaty S, et al. Clin Cancer Res. 2023 Aug 1;29(15):2781-2790. doi: 10.1158/1078-0432.CCR-23-0011. Clin Cancer Res. 2023. PMID: 37261814 Free PMC article. Clinical Trial.
40 results